Page 132 - 《中国药房》2024年14期

diabetes with SGLT-2 inhibitors：overview of the efficacy （BMS-512148），a potent sodium-glucose cotransporter
and safety of SGLT-2 inhibitors in type 2 diabetes mellitus type Ⅱ inhibitor，in animals and humans[J]. Drug Metab
[J]. J Fam Pract，2017，66（Suppl. 2）：S5-S12. Dispos，2010，38（3）：405-414.
[12] LU J M，FU L J，LI Y，et al. Henagliflozin monotherapy in [25] MUDERRISOGLU A，BABAOGLU E，KORKMAZ E T，
patients with type 2 diabetes inadequately controlled on et al. Effects of genetic polymorphisms of drug transporter
diet and exercise：a randomized，double-blind，placebo- ABCB1 （MDR1） and cytochrome P450 enzymes
controlled，phase 3 trial[J]. Diabetes Obes Metab，2021，23 CYP2A6，CYP2B6 on nicotine addiction and smoking
（5）：1111-1120. cessation[J]. Front Genet，2020，11：571997.
[13] SZEKERES Z，TOTH K，SZABADOS E. The effects of [26] ADAMS L A，ANSTEE Q M，TILG H，et al. Non-
SGLT2 inhibitors on lipid metabolism[J]. Metabolites， alcoholic fatty liver disease and its relationship with car‐
2021，11（2）：87. diovascular disease and other extrahepatic diseases[J].
[14] NEAL B，PERKOVIC V，MAHAFFEY K W，et al. Cana‐ Gut，2017，66（6）：1138-1153.
gliflozin and cardiovascular and renal events in type 2 dia‐ [27] SUMIDA Y，SEKO Y，YONEDA M，et al. Novel antidia‐
betes[J]. N Engl J Med，2017，377（7）：644-657. betic medications for non-alcoholic fatty liver disease
[15] HOEBEN E，WINTER W D，NEYENS M，et al. Popula‐ with type 2 diabetes mellitus[J]. Hepatol Res，2017，47
tion pharmacokinetic modeling of canagliflozin in healthy （4）：266-280.
volunteers and patients with type 2 diabetes mellitus[J]. [28] KAHL S，GANCHEVA S，STRAßBURGER K，et al. Em‐
Clin Pharmacokinet，2016，55（2）：209-223. pagliflozin effectively lowers liver fat content in well-
[16] CALADO J，LOEFFLER J，SAKALLIOGLU O，et al. Fa‐ controlled type 2 diabetes：a randomized，double-blind，
milial renal glucosuria：SLC5A2 mutation analysis and evi‐ phase 4，placebo-controlled trial[J]. Diabetes Care，2020，
dence of salt-wasting[J]. Kidney Int，2006，69（5）：852-855. 43（2）：298-305.
[17] BONNER C，KERR-CONTE J，GMYR V，et al. Inhibi‐ [29] MITSCHE M A，HOBBS H H，COHEN J C. Patatin-like
tion of the glucose transporter SGLT2 with dapagliflozin phospholipase domain-containing protein 3 promotes
in pancreatic alpha cells triggers glucagon secretion[J]. transfer of essential fatty acids from triglycerides to pho-
Nat Med，2015，21（5）：512-517. spholipids in hepatic lipid droplets[J]. J Biol Chem，2018，
[18] ENIGK U，BREITFELD J，SCHLEINITZ D，et al. Role 293（24）：9232.
of genetic variation in the human sodium-glucose cotran- [30] TAKEI D，ISHIHARA H，YAMAGUCHI S，et al. WFS1
sporter 2 gene（SGLT2）in glucose homeostasis[J]. Phar‐ protein modulates the free Ca concentration in the endoplas‐
2+
macogenomics，2011，12（8）：1119-1126. mic reticulum[J]. FEBS Lett，2006，580（24）：5635-5640.
[19] ORDELHEIDE A M，BÖHM A，KEMPE-TEUFEL D，et [31] Online Mendelian Inheritance in Man. Wolfram syndrome
al. Common variation in the sodium/glucose cotransporter 1（WFS1）：diabetes insipidus and diabetes mellitus with
2 gene SLC5A2 does neither affect fasting nor glucose- optic atrophy and deafness（DIDMOAD）[EB/OL]. [2024-
suppressed plasma glucagon concentrations[J]. PLoS One， 01-20]. https：//www. omim. org/entry/222300.% 20Acces-
2017，12（5）：e0177148. sed%2023%20Aug%202017.
[20] ZIMDAHL H，HAUPT A，BRENDEL M，et al. Influence [32] YAMADA T，ISHIHARA H，TAMURA A，et al. WFS1-
of common polymorphisms in the SLC5A2 gene on meta‐ deficiency increases endoplasmic reticulum stress，impairs
bolic traits in subjects at increased risk of diabetes and on cell cycle progression and triggers the apoptotic pathway
response to empagliflozin treatment in patients with diabe‐ specifically in pancreatic beta-cells[J]. Hum Mol Genet，
tes[J]. Pharmacogenet Genomics，2017，27（4）：135-142. 2006，15（10）：1600-1609.
[21] HODGES L M，MARKOVA S M，CHINN L W，et al. [33] HU R，CHEN X Y，SU Q，et al. ISR inhibition reverses
Very important pharmacogene summary：ABCB1（MDR1， pancreatic β-cell failure in Wolfram syndrome models[J].
P-glycoprotein）[J]. Pharmacogenet Genomics，2011，21 Cell Death Differ，2024，31（3）：322-334.
（3）：152-161. [34] NÁDASDI Á，GÁL V，MASSZI T，et al. Combined effect
[22] FANG X Y，MIAO R Y，WEI J H，et al. Advances in of pancreatic lipid content and gene variants（TCF7L2，
multi-omics study of biomarkers of glycolipid metabolism WFS1 and 11BHSD1）on B-cell function in middle aged
disorder[J]. Comput Struct Biotechnol J，2022，20：5935- women in a post hoc analysis[J]. Diabetol Metab Syndr，
5951. 2022，14（1）：106.
[23] HWANG J G，JEONG S I，KIM Y K，et al. Common [35] ZHANG Y Q，HAN S，LIU C C，et al. THADA inhibition
ABCB1 SNP，C3435T could affect systemic exposure of in mice protects against type 2 diabetes mellitus by im‐
dapagliflozin in healthy subject[J]. Transl Clin Pharmacol， proving pancreatic β -cell function and preserving β -cell
2022，30（4）：212-225. mass[J]. Nat Commun，2023，14（1）：1020.
[24] OBERMEIER M，YAO M，KHANNA A，et al. In vitro （收稿日期：2024-02-20 修回日期：2024-06-25）
characterization and pharmacokinetics of dapagliflozin （编辑：邹丽娟）

· 1794 · China Pharmacy 2024 Vol. 35 No. 14 中国药房 2024年第35卷第14期